scholarly journals Serum Free Triiodothyronine to Free Thyroxine Ratio Enables Early Prediction of the Outcome of Antithyroid Drug Therapy in Patients with Graves' Hyperthyroidism.

1991 ◽  
Vol 38 (6) ◽  
pp. 683-687 ◽  
Author(s):  
JUNICHI TAJIRI ◽  
SHIRO NOGUCHI ◽  
MITSUO MORITA ◽  
MASAAKI TAMARU ◽  
NOBUO MURAKAMI ◽  
...  
Keyword(s):  
Drug Therapy ◽  
Antithyroid Drug ◽  
Free Thyroxine ◽  
Early Prediction ◽  
Free Triiodothyronine ◽  
Serum Free ◽  
Antithyroid Drug Therapy

Insulin-like growth factor type 1 concentrations in hyperthyroid cats before and after treatment with thiamazole

2017 ◽  
Vol 20 (2) ◽  
pp. 179-183 ◽  
Author(s):  
Daphné Rochel ◽  
Myriam Burger ◽  
Patrick Nguyen ◽  
Laetitia Jaillardon
Keyword(s):  
Drug Therapy ◽  
Growth Factor ◽  
Limit Of Detection ◽  
Antithyroid Drug ◽  
Free Thyroxine ◽  
Insulin Like Growth Factor ◽  
Antithyroid Drug Therapy ◽  
Before And After ◽  
Factor Type

Objectives The aim of this study was to evaluate changes in circulating insulin-like growth factor type 1 (IGF-1) concentrations in hyperthyroid cats, before and after thiamazole treatment. Methods Thirty-four hyperthyroid cats were retrospectively included. Plasma free thyroxine (fT4) and IGF-1 concentrations were measured at diagnosis and 3 months after initiating antithyroid drug therapy. Results Median fT4 significantly decreased ( P <0.001) after treatment (from 78 pmol/l [range 43–122 pmol/l] to 31 pmol/l [range below assay limit of detection to 88 pmol/l]), whereas IGF-1 values significantly increased ( P <0.001) after treatment (from 117 ng/ml [33–341 ng/ml] to 221 ng/ml [36–865 ng/ml]). fT4 and IGF-1 concentrations were significantly negatively correlated both at diagnosis (r = −0.43, P = 0.01) and after treatment (r = −0.51, P = 0.002). Conclusions and relevance In cats, IGF-1 concentrations appear to be inversely proportional to the severity of hyperthyroidism and significantly increase after treatment with thiamazole.

Effects of Age and Health on the Euthyroid Reference Ranges for Serum Free Thyroxine and Free Triiodothyronine

1985 ◽  
Vol 24 (02) ◽  
pp. 57-65 ◽  
Author(s):  
J. E. M. Midgley ◽  
K. R. Gruner
Keyword(s):  
Lower Limit ◽  
Healthy Subjects ◽  
Thyroid Dysfunction ◽  
Reference Range ◽  
Free Thyroxine ◽  
Reference Ranges ◽  
Free Triiodothyronine ◽  
Serum Free ◽  
Young Subjects ◽  
Age Range

SummaryAge-related trends in serum free thyroxine (FT4) and free triiodothyronine (FT3) concentrations were measured in 7248 euthyroid subjects (age-range 3 months to 106 years). 5700 were patients referred to hospitals for investigation of suspected thyroid dysfunction, but who were diagnosed euthyroid. 1548 were healthy blood donors (age-range 18-63 years) with no indication of thyroid dysfunction. FT4 concentrations were little affected by the age, the sex or the state of health of the subjects in either group. Serum FT3 concentrations were significantly affected by both age and health factors. The upper limit of the euthyroid reference range for young subjects up to 15 years was about 20% higher (10.4 pmol/1) than for adult subjects older than 25 years (8.8 pmol/1). The change in the upper limits typical of young subjects to that typical of adults occurred steadily over the decade 15–25 years. After this age, little further change occurred, especially in healthy subjects. Additionally, the lower limit of the euthyroid range for FT3 was extended by the inclusion in the reference group of patients referred to hospitals. Compared with the lower limit of the FT3 range for healthy subjects (5 pmol/1), the corresponding limit for referred subjects (young or adult) was 3.5–3.8 pmol/1. Broadening of the FT3 reference range was probably brought about by a significant number of patients in the hospital-referred group with the “1OW-T3 syndrome” of mild non-thyroidal illness. Accordingly, FT3 was inferior to FT4 in the discrimination of hypothyroidism, as FT4 was unaffected by this phenomenon. Effects of age and non-thyroidal illness on serum FT3 concentrations require great care when selecting subjects for a laboratory euthyroid reference range typical of the routine workload. Constraints on the choice of subjects for FT4 reference ranges are less stringent.

A second course of antithyroid drug therapy is effective in patients with relapsed Graves' disease

2018 ◽  
Author(s):  
Khyatisha Seejore ◽  
Fozia Nawaz ◽  
Katherine Kelleher ◽  
Julie Kyaw-Tun ◽  
Julie Lynch ◽  
...  
Keyword(s):  
Drug Therapy ◽  
Antithyroid Drug ◽  
Graves Disease ◽  
Antithyroid Drug Therapy

Successful Treatment of Graves Disease in Pregnancy with Lugol's Iodine

2000 ◽  
Vol 45 (1) ◽  
pp. 20-21 ◽  
Author(s):  
A. Jamieson ◽  
C.G. Semple
Keyword(s):  
Drug Therapy ◽  
Successful Treatment ◽  
Surgical Intervention ◽  
Antithyroid Drug ◽  
Primary Treatment ◽  
Graves Disease ◽  
Lugol’S Iodine ◽  
Organic Iodine ◽  
Antithyroid Drug Therapy ◽  
In Pregnancy

We report a case of Grave's disease in pregnancy complicated by intolerance of standard antithyroid drug therapy. We describe the success of prolonged use of organic iodine as a primary treatment prior to surgical intervention.

scholarly journals Falsely High Serum Free Triiodothyronine and Free Thyroxine Concentrations Attributable to Anti-Diiodothyronine and Anti-Triiodothyronine Antibodies

2005 ◽  
Vol 51 (6) ◽  
pp. 1071-1072 ◽  
Author(s):  
Kunihiro Iwahara ◽  
Chizuko Tanabe ◽  
Kozo Nishiyama ◽  
Hiroyuki Ohashi ◽  
Masato Maekawa
Keyword(s):  
High Serum ◽  
Free Thyroxine ◽  
Free Triiodothyronine ◽  
Serum Free

Erratum

1989 ◽  
Vol 121 (2) ◽  
pp. 304
Author(s):  
H. Schleusener ◽  
J. Schwander ◽  
C. Fischer ◽  
R. Holle ◽  
G. Holl ◽  
...  
Keyword(s):  
Drug Therapy ◽  
Relapse Rate ◽  
Clinical Course ◽  
Antithyroid Drug ◽  
Graves Disease ◽  
Trh Test ◽  
Prospective Multicentre Study ◽  
Antithyroid Drug Therapy ◽  
Significant Difference ◽  
The Individual

Abstract. Graves' disease is an autoimmune disease characterized by a course of remission and relapse. Since the introduction of antithyroid drug treatment, various parameters have been tested for their ability to predict the clinical course of a patient with Graves' disease after drug withdrawal. Nearly all these studies were retrospective and often yielded conflicting results. In a prospective multicentre study with a total of 451 patients, we investigated the significance of a variety of routine laboratory and clinical parameters for predicting a patient's clinical course. Patients who had positive TSH receptor antibodies activity at the end of therapy showed a significantly higher relapse rate than those without (P < 0.001). However, the individual clinical course cannot be predicted exactly (sensitivity 0.49, specificity 0.73, N = 391). The measurement of microsomal (P = 0.99, sensitivity 0.37, specificity 0.63, N = 275) or thyroglobulin antibodies (P = 0.76, sensitivity 0.18, specificity 0.84, N = 304) at the end of antithyroid drug therapy did not show a statistically significant difference in the antibody titre between the patients of the relapse and those of the remission group. Additionally, HLA-DR typing (HLA-DR3: P = 0.37, sensitivity 0.36, specificity 0.58, N = 253) was proven to be unsuitable for predicting a patient's clinical course. Patients with abnormal suppression or an abnormal TRH test at the end of antithyroid drug therapy relapse significantly more often (P< 0.001) than patients with normal suppression or normal TRH test. Patients with a large goitre also have a significantly (P< 0.001) higher relapse rate than those with only a small enlargement. The sensitivity and specificity values of all these parameters, however, were too low to be useful for daily clinical decisions in the treatment of an individual patient. This is also true for the combinations of different parameters. Though the highest sensitivity value (0.94) was found for a combination of the suppression and the TRH test at the end of therapy, the very low specificity value (0.13) for this combination reduced its clinical usefulness.

scholarly journals Misleading results from immunoassays of serum free thyroxine in the presence of rheumatoid factor

1997 ◽  
Vol 43 (6) ◽  
pp. 957-962 ◽  
Author(s):  
Anthony G W Norden ◽  
Rodwin A Jackson ◽  
Lorraine E Norden ◽  
A Jane Griffin ◽  
Margaret A Barnes ◽  
...  
Keyword(s):  
Thyroid Hormone ◽  
Rheumatoid Factor ◽  
Equilibrium Dialysis ◽  
Thyroid Stimulating Hormone ◽  
Normal Serum ◽  
Free Thyroxine ◽  
Free Triiodothyronine ◽  
Serum Free ◽  
Serum Free Thyroxine ◽  
Stimulating Hormone

Abstract A novel interference with measurements of serum free thyroxine (FT4) caused by rheumatoid factor (RhF) is described. We found misleading, sometimes gross, increases of FT4 results in 5 clinically euthyroid elderly female patients with high RhF concentrations. All 5 patients had high FT4 on Abbott AxSYM® or IMx® analyzers. “NETRIA” immunoassays gave misleading results in 4 of the 5 patients; Amerlex-MAB® in 2 of 4 patients; AutoDELFIA®in 2 of the 5; and Corning ACS-180® and Bayer Diagnostics Immuno 1® in 1 of the 5. BM-ES700® system results for FT4 in these women remained within the reference range. Results for serum T4, thyroid-stimulating hormone, free triiodothyronine, thyroid-hormone-binding globulin, and FT4 measured by equilibrium dialysis were normal in all 5 patients. Drugs, albumin-binding variants, and anti-thyroid-hormone antibodies were excluded as interferences. Addition to normal serum of the RhF isolated from each of the 5 patients increased the apparent FT4 (Abbott AxSYM). Screening of 83 unselected patients demonstrated a highly significant positive correlation between FT4 (Abbott AxSYM) and RhF concentrations. Discrepant, apparently increased FT4 with a normal result for thyroid-stimulating hormone should lead to measurement of the patient’s RhF concentration.

scholarly journals Clinical usage recommendations and analytic performance goals for total and free triiodothyronine measurements

1996 ◽  
Vol 42 (1) ◽  
pp. 155-159 ◽  
Author(s):  
G G Klee
Keyword(s):  
Heart Function ◽  
Hormone Replacement ◽  
Antithyroid Drug ◽  
Cross Reactivity ◽  
Free Triiodothyronine ◽  
Clinical Role ◽  
Reverse T3 ◽  
Antithyroid Drug Therapy ◽  
Total Triiodothyronine ◽  
Thyroid Hormone Replacement Therapy

Abstract The major clinical role for total triiodothyronine (TT3) and (or) free T3 (FT3) is the assessment of hyperthyroidism in patients with suppressed sensitive thyrotropin (sTSH) concentrations. The assays are particularly important in hyperthyroid patients with normal free thyroxine (FT4) concentrations to assess potential T3 thyrotoxicosis. Other specialized uses for T3 and FT3 measurements are monitoring thyroid hormone replacement therapy, the evaluation of amiodarone-induced thyrotoxicosis, and predicting outcome of antithyroid drug therapy in patients with Graves hyperthyroidism. The roles of these tests in assessing heart function in cardiopulmonary bypass surgery, evaluation of patients with neuropsychiatric disorders, and monitoring of patients on anticonvulsant therapy are not well defined. These assays are not recommended for diagnosis of hypothyroidism. Analytic recommendations include CV &lt; 5.2% for T3 and &lt; 3.8% for FT3; &lt; 0.2% cross-reactivity with L-T4; and &lt; 1.0% cross-reactivity with D-T4, D-T3, and reverse T3.

Sign in / Sign up

Export Citation Format

Share Document